CN117241797A - 治疗前列腺癌的方法 - Google Patents

治疗前列腺癌的方法 Download PDF

Info

Publication number
CN117241797A
CN117241797A CN202280032513.3A CN202280032513A CN117241797A CN 117241797 A CN117241797 A CN 117241797A CN 202280032513 A CN202280032513 A CN 202280032513A CN 117241797 A CN117241797 A CN 117241797A
Authority
CN
China
Prior art keywords
prostate cancer
compound
cells
acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032513.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·马拉泰斯塔
E·H·菲尔瓦罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN117241797A publication Critical patent/CN117241797A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280032513.3A 2021-03-12 2022-03-10 治疗前列腺癌的方法 Pending CN117241797A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
US63/160,319 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
CN117241797A true CN117241797A (zh) 2023-12-15

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032513.3A Pending CN117241797A (zh) 2021-03-12 2022-03-10 治疗前列腺癌的方法

Country Status (6)

Country Link
US (1) US12016847B2 (https=)
EP (1) EP4304589A1 (https=)
JP (1) JP2024510975A (https=)
KR (1) KR20230156107A (https=)
CN (1) CN117241797A (https=)
WO (1) WO2022192481A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
WO2013046635A1 (ja) 2011-09-28 2013-04-04 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2015131005A1 (en) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
AU2015358334A1 (en) * 2014-12-05 2017-06-08 Dana-Farber Cancer Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Also Published As

Publication number Publication date
US12016847B2 (en) 2024-06-25
JP2024510975A (ja) 2024-03-12
EP4304589A1 (en) 2024-01-17
US20220296574A1 (en) 2022-09-22
KR20230156107A (ko) 2023-11-13
WO2022192481A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US20220265618A1 (en) Methods of treating prostate cancer
US8110550B2 (en) HDAC inhibitors and hormone targeted drugs for the treatment of cancer
US8853277B2 (en) Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US8445435B2 (en) Mast cell stabilizers in the treatment of obesity
US20210137915A1 (en) Pharmaceutical use and pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts
CN117241797A (zh) 治疗前列腺癌的方法
US20250268876A1 (en) Treatment of hidradenitis suppurativa with orismilast
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US20200009088A1 (en) Compositions and methods for treating androgen-independent cancer
TW201247612A (en) Compositions for treating kidney disorders
AU2018218341B2 (en) Treatment of cancer and inhibition of metastasis
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
KR102740381B1 (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
Bochenek et al. Diagnosis, prevention and treatment of aspirin-induced asthma and rhinitis
HK40099691A (zh) 用於治疗前列腺癌的溴结构域(bet)抑制剂
CN103153309A (zh) 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
WO2004084874A2 (en) Mtp inhibitors for inhibiting inflammation
WO2025090967A9 (en) Pharmacological agonist of klf2 reduces osteoclast differentiation, inflammation, and covid
CN118203578A (zh) 奥赛利定在制备预防或治疗围术期低体温的药物中的应用
CN120617521A (zh) Ripk 3调控小胶质细胞m1/m2极化在制备慢性疼痛治疗药物中的应用
CN121550196A (zh) 靶向抑制kcnq1、kcne2复合体通道的天然产物的应用方法
GB2454923A (en) Salt of salicylic acid for use in treating early stage prostate cancer
Asaoka et al. Effects of acid-suppressive medications use on bone metabolism
KR20180081938A (ko) 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination